CSL Ltd ADR CSLLY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $30.94
- Day Range
- $30.39–31.05
- 52-Week Range
- $16.01–36.29
- Bid/Ask
- $25.23 / $42.94
- Shares Outstanding
- 1.92B
- Market Cap
- $58.50B
- Volume/Avg
- 51,198 / 165,213
Key Statistics
- Price/Earnings (Normalized)
- 20.93
- Price/Sales
- 3.80
- Dividend Yield (Trailing)
- 2.37%
- Dividend Yield (Forward)
- 2.37%
- Dividend Payment Schedule
- Apr, Oct
- Total Yield
- 3.56%
Company Profile
CSL is one of the largest global biotech companies and has three main segments. CSL Behring uses either plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D record, and its product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and one-fourth in Europe.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Large Core
- Total Number of Employees
- 30,000
- Website
- https://www.csl.com
Competitors
Valuation
|
Metric
|
CSLLY
|
4502
|
SNY
|
|---|---|---|---|
Price/Earnings (Normalized) | 20.93 | 47.48 | 11.55 |
Price/Book Value | 4.01 | 1.18 | 1.35 |
Price/Sales | 3.80 | 1.93 | 1.73 |
Price/Cash Flow | 16.98 | 10.79 | 7.15 |
Price/Earnings
CSLLY
4502
SNY
Financial Strength
|
Metric
|
CSLLY
|
4502
|
SNY
|
|---|---|---|---|
Quick Ratio | 0.88 | 0.54 | 0.49 |
Current Ratio | 2.21 | 1.14 | 0.99 |
Interest Coverage | −8.46 | 0.07 | 8.05 |
Quick Ratio
CSLLY
4502
SNY
Profitability
|
Metric
|
CSLLY
|
4502
|
SNY
|
|---|---|---|---|
Return on Assets (Normalized) | 8.38% | 5.53% | 7.96% |
Return on Equity (Normalized) | 17.61% | 11.34% | 14.96% |
Return on Invested Capital (Normalized) | 11.10% | 7.74% | 11.28% |
Return on Assets
CSLLY
4502
SNY
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|j&$j$Z | LOCK|%BS&g | $128B | |||
| Moderna Inc
MRNA
| LOCK|Yd!t&^x | LOCK|#Q# | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|C&rv^@Q | LOCK|@@&& | $76B | |||
| argenx SE ADR
ARGX
| LOCK|sTt>Qh | LOCK|<?w | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|lt<$&w | LOCK|Xc$ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|#MNF>% | LOCK|!Hcg | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|n@Bgj@Z | LOCK|!#TF& | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|X<#@$?Z | LOCK|dJ | $24B | |||
| Incyte Corp
INCY
| LOCK|blDTby? | LOCK|BHm | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|$XbN#Z | LOCK|^sh | $15B |
United States